Daraxonrasib, a first-in-class RAS inhibitor developed by Revolution Medicines, nearly doubled overall survival for patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 clinical trial — delivering the most significant survival improvement in this disease in more than a decade and cracking open what oncologists have long called one of medicine's most stubborn biological barriers.
What the Trial Found
The international Phase 3 study enrolled 500 patients who had already received at least one prior line of therapy for metastatic pancreatic ductal adenocarcinoma — the most common and lethal form of pancreatic cancer. Patients were randomized to receive either daraxonrasib or physician's choice chemotherapy, the current standard of care for second-line treatment in this setting.
The results were striking by any measure in oncology. Daraxonrasib produced a median overall survival of 13.2 months, compared with 6.7 months in the chemotherapy arm — a hazard ratio of 0.40 that translates directly to a 60 percent reduction in the risk of dying at any given point during the study. Median progression-free survival more than doubled as well, improving from 3.6 months on chemotherapy to 7.2 months on daraxonrasib. The findings were simultaneously published in the New England Journal of Medicine following their presentation in the plenary session of the American Society of Clinical Oncology annual meeting in Chicago on May 31.
Why RAS Has Been So Hard to Target
Pancreatic cancer has long been one of oncology's most intractable problems, and understanding why requires a brief detour into molecular biology. The disease is typically diagnosed at an advanced stage — roughly 80 percent of patients present with locally advanced or metastatic disease — and the five-year survival rate has stubbornly remained below 13 percent for decades despite sustained research investment. A central reason is that pancreatic tumors are driven almost universally by mutations in the RAS family of proteins, particularly KRAS, which were long considered "undruggable" because the protein's smooth surface offers few obvious attachment points for small-molecule drugs.
Earlier attempts to block RAS signaling by targeting downstream proteins produced only modest and short-lived responses. The cancer cells found workarounds with unsettling reliability, and the field largely gave up on direct RAS inhibition as a primary strategy for more than two decades. The emergence of KRAS G12C inhibitors in lung cancer beginning around 2021 reopened the possibility — but KRAS G12C is a minority mutation in pancreatic cancer, limiting that approach's applicability to the broader patient population.
"We have been trying to drug RAS for 40 years," a senior oncologist at Dana-Farber Cancer Institute said in a statement accompanying the results. "What we are seeing with daraxonrasib in the Phase 3 data is a genuine paradigm shift. These are patients who had no good options. The hazard ratio of 0.40 is a number this disease has never produced before."
The Science Behind Daraxonrasib
Revolution Medicines developed daraxonrasib as a RAS(ON) inhibitor — a mechanism that targets the active, oncogenic form of the RAS protein and locks it into an inactive configuration rather than attempting to block downstream signaling. The approach is designed to work across multiple RAS mutation subtypes, including KRAS G12D and G12V, which together account for the majority of KRAS mutations in pancreatic tumors. This broad molecular coverage is a key reason the drug performed well across the heterogeneous population enrolled in RASolute 302.
The trial's safety profile added to the case for approval. The most common adverse events were skin rash and gastrointestinal symptoms, which were generally manageable with dose modifications and supportive care. Serious adverse events occurred at lower rates than in the chemotherapy comparator arm — an unusual finding in cancer drug trials, where experimental agents frequently carry significant toxicity burdens of their own. No new safety signals emerged during the study period.
What Comes Next
Revolution Medicines announced it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, relying on the RASolute 302 data as the primary evidence package. The FDA previously granted daraxonrasib breakthrough therapy designation, which is intended to expedite development and review for drugs showing substantial improvement over existing therapies for serious or life-threatening conditions. If that designation translates into an accelerated review timeline, a potential approval could arrive in 2027.
If approved, daraxonrasib would become the first RAS-targeted therapy approved for pancreatic cancer — a milestone that researchers believe could eventually reshape how the disease is managed not only in the second-line setting but throughout the treatment continuum. Several investigational trials are already being designed to evaluate the drug in combination with front-line gemcitabine-based chemotherapy and as a maintenance therapy following initial response. Early-line trials, if successful, could expand the patient population that benefits substantially.
For a disease that kills roughly 54,000 Americans each year according to the American Cancer Society — making it the third-leading cause of cancer death in the United States — even a modest improvement in the survival curve matters profoundly to patients and families. Doubling median survival, as daraxonrasib did in this trial, is something different entirely. It is the kind of result that changes the standard of care. The question now is how quickly the regulatory and clinical infrastructure can move to put it in patients' hands.